Company intelligence / Profile preview

BHV Pharma

Research Triangle Park, North Carolina, United Statesbhvpharma.hu ↗

Ownership: Private
Development stage: Phase 2

Overview

BHV Pharma was developing remogliflozin etabonate, an SGLT2 inhibitor that was in Phase 2 clinical development for type 2 diabetes and NASH at the time of acquisition.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

remogliflozin etabonate

Phase 2

Indications: Type 2 diabetes, Non-alcoholic steatohepatitis

Partnerships

Kissei Pharmaceuticals (Japan)

Beyond the preview

Go deeper on BHV Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHV Pharma.

Explore the full profile